Search results

2618 results

Sorted by Date . Sort by Relevance

  1. Sarcoma

    Everything NICE has said on sarcoma in an interactive flowchart

  2. Brain tumours and metastases

    Everything NICE has said on brain tumours in adults, including cancer, in an interactive flowchart

  3. Renal cancer

    Everything NICE has said on renal (kidney) cancer in an interactive flowchart

  4. Bladder cancer

    Everything NICE has said on bladder cancer in adults in an interactive flowchart

  5. Upper aerodigestive tract cancer

    Everything NICE has said on assessing and managing upper aerodigestive tract cancer in young people and adults in an interactive flowchart

  6. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and

  7. Endocrine cancers

    Everything NICE has said on endocrine cancers in an interactive flowchart

  8. Oesophageal and gastric cancer

    Everything NICE has said on assessing and managing non-stromal oesophageal and gastric cancer in adults

  9. Ovarian cancer

    Everything NICE has said on recognising and managing ovarian cancer in an interactive flowchart

  10. Prostate cancer

    Everything NICE has said on diagnosing and treating prostate cancer in an interactive flowchart

  11. Melanoma

    Everything NICE has said assessing and managing melanoma in an interactive flowchart

  12. Skin cancer

    Everything NICE has said on skin cancers, including melanoma, basal cell carcinoma and squamous cell carcinoma in an interactive flowchart

  13. Neutropenic sepsis

    Everything NICE has said on preventing, identifying and managing neutropenic sepsis in children, young people and adults in an interactive flowchart

  14. Board committees

    Audit and risk committee The audit and risk committee provides an independent, objective review of arrangements for internal control within NICE. The

  15. NICE chairman Sharmila Nebhrajani begins her new role

    NICE is delighted to announce that today (26 May 2020) Sharmila Nebhrajani, OBE, has taken up her position as its new chairman following her appointment by the Secretary of State for Health and Social Care and an independent open recruitment process.

  16. Preventing type 2 diabetes

    Everything NICE has said on preventing type 2 diabetes in an interactive flowchart

  17. Hypertension in pregnancy

    Everything NICE has said on diagnosing and managing hypertension in pregnancy in an interactive flowchart

  18. Diagnostics guidance static list

    The following published diagnostics assessments have been transferred to the static list. Guidance is moved to the static list following consultation

  19. Sunlight exposure: risks and benefits

    Everything NICE has said on how to communicate the risks and benefits of natural sunlight exposure in an interactive flowchart

  20. Committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  21. Scholars

    Scholarships are one year opportunities to improve quality of care and contribute to your professional development

  22. MTA process timeline

    These are the main stages in multiple technology appraisals process. Timings are approximate. For a full description of the appraisal process see our

  23. COVID-19 rapid guideline: interstitial lung disease (NG177)

    The purpose of this guideline is to maximise the safety of adults with interstitial lung disease, including idiopathic pulmonary fibrosis and pulmonary sarcoidosis, during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  24. COVID-19 rapid guideline: chronic kidney disease (NG176)

    The purpose of this guideline is to maximise the safety of adults with chronic kidney disease during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  25. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults

  26. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months

  27. Brand guidelines

    This is an overview of the NICE brand identity incorporating who we are, what we do, and the values underpinning our work. Who we are NICE is the...

  28. Pneumonia

    Everything NICE has said on assessing and managing community- and hospital-acquired pneumonia in an interactive flowchart

  29. Past appeals and decisions

    Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal short title Appeal hearing date TA111 Alzheimer´s

  30. Acute upper gastrointestinal bleeding

    Everything NICE has said on risk assessment and management of acute upper gastrointestinal bleeding in people 16 years and older in an interactive flowchart

  31. Transition from children's to adults' services

    Everything NICE has said on the transition from children's to adults' services for young people in health or social care in an interactive flowchart

  32. Multimorbidity

    Everything NICE has said on optimising care for people with 2 or more long-term health conditions in an interactive flowchart